US: Omnicare to pay $28 million to settle charges it got kickbacks from Abbott Labs
Omnicare the largest nursing home pharmacy in the United States, will pay about $28.1 million to resolve civil charges that it sought and received kickbacks from Abbott Laboratories to promote the drug maker’s anti-seizure drug Depakote, the US Justice Department said Monday.
Omnicare was acquired by CVS Health Corp in 2015, about six years after Omnicare put a stop to the conduct at the heart of Monday’s settlement, the Justice Department added.
The Justice Department said Omnicare disguised the kickbacks it received from Abbott by claiming they were “grants” and “educational funding.”
Those payments, however, were part of a plan by the drug maker to get physicians to prescribe Depakote to elderly nursing home patients. Omnicare solicited the payments via its “Re*View” program, which in internal documents it called its “one extra script per patient” program.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Australian Law Firms Target ACCC Talent Ahead of Major Merger Reforms
May 11, 2025 by
CPI
What the Google Antitrust Trial Has Revealed So Far
May 11, 2025 by
CPI
Hamlin Remains Confident in 23XI, Front Row Antitrust Case Against NASCAR
May 11, 2025 by
CPI
Google Faces €2.97 Billion Lawsuit in Italy Over Alleged Market Abuse
May 11, 2025 by
CPI
UFC Finalizes $375 Million Settlement in Fighter Antitrust Case
May 11, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece